Multiple analyst firms, including Needham, Mizuho, and Zacks, issued rating changes and coverage updates for Harmony Biosciences.
1 report, 1 independent
Updated Oct 20
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Multiple analyst firms, including Needham, Mizuho, and Zacks, issued rating changes and coverage updates for Harmony Biosciences.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Mizuho Securities
Japanese investment banking company
Nothing else this week.
Related events
- Mizuho Securities increased its price objective, while Citigroup reaffirmed its market outperform rating for a stock, with MarketBeat reporting the average rating.
- Banks like Mizuho, Deutsche Bank, and Goldman Sachs maintained or raised ratings for Harmony Biosciences, citing benefits from tariffs and onshoring trends for AI stocks.
- Multiple financial firms, including TD Cowen, Goldman Sachs, and Mizuho, issued various rating changes and price target updates across several stocks.